Drugs Made In America Acquisition Corp. closes $200M IPO, deposits $201M in trust

Drugs Made In America Acquisition Corp.

Closed IPO of 20,000,000 units at $10.00 per unit for gross proceeds of $200 million.
Simultaneous private placement of 400,000 units to sponsor for $4 million, bringing total trust to $201 million.
Units trade on Nasdaq under DMAAU; ordinary shares (DMAA) and rights (DMAAR) to trade separately later.
Clear Street acted as sole book-running manager; offering made under effective S-1 registration statement.
Underwriters have 45-day option for up to 3M additional units to cover over-allotments.

item 1.01 item 3.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Drugs Made In America Acquisition Corp.: Adopted Second Amended and Restated Memorandum and Articles of Association in connection with the IPO (effective 2025-01-07).

Change: charter amendment
Effective: 2025-01-07

Exact text from the filing

On January 7, 2025, and in connection with the IPO, the Company adopted its Second Amended and Restated Memorandum and Articles of Association.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Drugs Made In America Acquisition Corp. filing history →

Source: SEC EDGAR

accession 0001213900-25-008377

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.